A series of BH3 sensitizer peptides that bind Bcl-xL with sub-nanomolar affinity and selectivity up to 1000-fold over each of the competing pro-survival proteins, have been tested in vitro in a panel of cancer cell lines, showing reduced proliferation in cells expressing high level of Bcl-xL protein [164]. The gene discussed is BCL2L1; the disease is cancer.